Skip to main content

Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.

Publication ,  Journal Article
Othus, M; Mukherjee, S; Sekeres, MA; Godwin, J; Petersdorf, S; Appelbaum, FR; Erba, H; Estey, E
Published in: Leukemia
August 2016

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

August 2016

Volume

30

Issue

8

Start / End Page

1779 / 1780

Location

England

Related Subject Headings

  • Practice Guidelines as Topic
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Immunology
  • Idarubicin
  • Humans
  • Guideline Adherence
  • Female
  • Daunorubicin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Othus, M., Mukherjee, S., Sekeres, M. A., Godwin, J., Petersdorf, S., Appelbaum, F. R., … Estey, E. (2016). Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia, 30(8), 1779–1780. https://doi.org/10.1038/leu.2016.48
Othus, M., S. Mukherjee, M. A. Sekeres, J. Godwin, S. Petersdorf, F. R. Appelbaum, H. Erba, and E. Estey. “Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.Leukemia 30, no. 8 (August 2016): 1779–80. https://doi.org/10.1038/leu.2016.48.
Othus M, Mukherjee S, Sekeres MA, Godwin J, Petersdorf S, Appelbaum FR, et al. Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia. 2016 Aug;30(8):1779–80.
Othus, M., et al. “Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.Leukemia, vol. 30, no. 8, Aug. 2016, pp. 1779–80. Pubmed, doi:10.1038/leu.2016.48.
Othus M, Mukherjee S, Sekeres MA, Godwin J, Petersdorf S, Appelbaum FR, Erba H, Estey E. Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia. 2016 Aug;30(8):1779–1780.

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

August 2016

Volume

30

Issue

8

Start / End Page

1779 / 1780

Location

England

Related Subject Headings

  • Practice Guidelines as Topic
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Immunology
  • Idarubicin
  • Humans
  • Guideline Adherence
  • Female
  • Daunorubicin